- 期刊
- OpenAccess
Risk and Predictors of Patients Receiving Neoadjuvant Chemotherapy Followed by Radical Cystectomy or Transurethral Resection Alone for Muscle-Invasive Bladder Cancer: A Single-Institute Experience
摘要
Background: Upper urinary tract urothelial carcinoma and muscle-invasive bladder cancer (MIBC) incidence rates are high in Taiwan. Our patients with MIBC are commonly managed with a radical cystectomy (RC); however, recurrence rates remain high. Aim: We aimed to establish a protocol regarding neoadjuvant chemotherapy (NAC) followed by RC or transurethral resection (TUR) alone from 2008 to 2013. We outline the efficacy and prognosis of NAC followed by RC. Methods: This was a retrospective study. The clinical data of 38 patients who underwent NAC from 2008 to 2013 at a single institution were retrospectively reviewed. Patients were divided into Group 1 (NAC with RC) and Group 2 (NAC with TUR alone). Age, sex, tumor size, prechemotherapy characteristics, and oncological outcomes were analyzed. Results: Group 1 had worse chemotherapy responses than Group 2 (48% vs. 71%, P = 0.0002). There were no significant differences in the 3-year progression-free survival and overall survival (OS) between the groups. High-risk patients were defined as having a tumor size ＞5 cm, concurrent hydronephrosis, and adverse pathological features. High-risk Group 1 patients had a better 3-year OS than high-risk Group 2 patients (13/17, 76%; and 3/5, 63%; respectively). Conclusion: In high-risk patients or patients with poor chemotherapy responses, NAC followed by RC with pelvic lymph node dissection resulted in a significantly increased 3-year OS. NAC with TUR alone was suitable only for low-risk patients with good chemotherapy responses.
延伸閱讀
- Hsu, F. M., Cheng, J. C. H., Pu, Y. S., Lin, C. C., & Lai, M. K. (2006). Transurethral Resection of Bladder Tumors Followed by Radiotherapy with or without Chemotherapy for Bladder Preservation in Patients with Invasive Bladder Transitional Cell Carcinoma: Preliminary Ntuh. 放射治療與腫瘤學, 13(2), 103-116. https://doi.org/10.6316/TRO/200613(2)103
- Lee, F. C., Harris, W., Cheng, H. H., Shenoi, J., Zhao, S., Wang, J., Champion, T., Izard, J., Gore, J. L., Porter, M., Yu, E. Y., & Wright, J. L. (2013). Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology, 2013(), 45-50. https://doi.org/10.1155/2013/317190
- Chen, C. H., Lin, E. K., Lu, Y. J., & Wei, P. L. (2018). The Improvements of Outcomes in Stage II-III, Middle and Lower Third Rectal Cancer Patients in Recently Ten Years: The Improvements are Associated with Neo-adjuvant Concurrent Chemo-radiotherapy. 中華民國大腸直腸外科醫學會雜誌, 29(1), 64-71. https://doi.org/10.6312/SCRSTW.2018.29(1).10626
- Wu, C. T., Lai, C. H., Hung, C. H., Liu, K. C., Chen, M. F., & Chen, W. C. (2014). Preliminary Results of Biochemical Outcomes, Survival and Toxicity in Patients Treated with Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. 放射治療與腫瘤學, 21(1), 1-12. https://doi.org/10.6316/TRO/201421(1)1
- Chang, P. K., Jao, S. W., Wu, C. C., Lee, C. C., Lee, T. Y., & Hsiao, C. W. (2013). Outcomes of Neoadjuvant Chemoradiation Therapy for Locally Advanced Rectal Cancer: The Effect of Preoperative Chemoradiotherapy Followed by Additional Chemotherapy on Advanced Rectal Cancer. 中華民國大腸直腸外科醫學會雜誌, 24(3), 80-86. https://doi.org/10.6312/SCRSTW.2013.24(3).10207